Natera, Inc. (NTRA), a molecular diagnostics company based in Austin, Texas, has been one of the healthcare sector's strongest performers. The stock has more than doubled from its 52-week low near $157 to a recent close around $320, and it briefly touched an all-time high of roughly $343. That surge has naturally pushed investors to ask what comes next — and $400, a clean psychological round number just beyond the record high, has become a focal point in market discussion.
Reaching $400 would require a move of about 25% from current levels and would take the shares decisively into uncharted territory above the existing peak. It is far enough away to be meaningful, yet close enough to be a plausible subject of debate rather than pure speculation.
Natera develops and commercializes non-invasive, cell-free DNA (cfDNA) tests across three segments: oncology, women's health, and organ health. Its flagship oncology product, Signatera, is a personalized tumor-informed test used to detect minimal residual disease (MRD) and monitor cancer recurrence. The company also sells Panorama, a non-invasive prenatal test, Horizon carrier screening, and Prospera, a transplant-rejection monitoring test.
The business is growing quickly. Trailing-twelve-month revenue sits near $2.7 billion, up roughly 36% year over year, and quarterly revenue growth has stayed in the high-thirties percentage range. Importantly, however, the company is still not GAAP profitable, posting a net loss near $192 million over the past twelve months. It maintains a strong balance sheet, with about $1.09 billion in cash against roughly $238 million in total debt.
The core bull case rests on Natera's leadership in the fast-growing MRD market. Signatera is already ordered by a substantial share of U.S. oncologists each quarter, and the company has expanded the test across a growing list of solid tumor types. A significant catalyst arrived when the U.S. Food and Drug Administration approved Signatera CDx as a companion diagnostic for adjuvant immunotherapy in muscle-invasive bladder cancer — described as a first for a blood-based MRD companion diagnostic.
Management has also raised its 2026 revenue guidance to a range of roughly $2.74 billion to $2.82 billion, reflecting confidence in continued test-volume growth. Expanding gross margins, a broad pipeline of clinical data, and new product launches across genomics and transplant monitoring give the growth story multiple legs. If revenue keeps compounding at a mid-thirties pace and operating leverage begins to show, the market could justify a higher multiple and a march toward $400.
The primary obstacle is valuation. Because Natera is not yet profitable, it cannot be evaluated on a conventional price-to-earnings (P/E) basis, and its price-to-sales ratio is well above typical market benchmarks. That means the shares price in substantial future growth, leaving limited tolerance for any slowdown in test volumes or reimbursement pressure.
Competition is another concern. Natera faces rivals in oncology diagnostics including Exact Sciences (EXAS) and Guardant Health (GH), as well as large, well-capitalized players such as Illumina (ILMN), Thermo Fisher Scientific (TMO), and Danaher (DHR). Reimbursement decisions from Medicare and commercial insurers, ongoing litigation, and the pattern of insider selling all add risk to the near-term picture.
Wall Street remains broadly constructive but notably short of $400. The consensus rating is a Buy, with an average twelve-month price target near $337 and a median near $348. After Natera's latest quarterly report, several firms lifted their targets into the $350 to $375 range — including Citigroup, Piper Sandler, Guggenheim, JP Morgan, RBC Capital, and Evercore ISI — while Wells Fargo maintained a more cautious Equal-Weight stance.
The gap is telling: even the most bullish published analyst target of roughly $375 sits below the $400 level investors are asking about. Reaching $400 would therefore require the company to exceed current Street expectations and for the market to award an even richer multiple than analysts currently model.
From a technical analysis perspective, the all-time high near $343.18 is the defining resistance level. A decisive close above that zone would establish a new breakout and open the path toward the $375 area and, ultimately, the $400 psychological milestone. On the downside, the $300 round-number level serves as a key support zone, followed by the mid-$280s, where the lowest current analyst target sits.
For traders monitoring whether NTRA can sustain a push toward new highs, automated tools can help filter the noise. Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously scan thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. These signals are designed to help traders spot opportunities, track existing positions, and identify changing market trends more efficiently, rather than relying on manual chart reading alone.
A move to $400 is plausible in a strong scenario but is not currently supported by consensus analyst expectations. The strongest drivers are Natera's leadership in MRD testing, its FDA-approved companion diagnostic, and sustained high-thirties revenue growth. The principal risks are a premium valuation, persistent GAAP losses, intensifying competition, and reimbursement uncertainty.
Investors should monitor test-volume trends, gross-margin progress, the pace of reimbursement coverage for Signatera, and whether the stock can hold above its prior highs. A breakout above $343 with improving profitability would make $400 far more credible; a failure to clear that level would likely keep the milestone out of reach for now.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, NTRA has been loosely correlated with ISRG. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if NTRA jumps, then ISRG could also see price increases.
| Ticker / NAME | Correlation To NTRA | 1D Price Change % | ||
|---|---|---|---|---|
| NTRA | 100% | +1.37% | ||
| ISRG - NTRA | 53% Loosely correlated | +0.71% | ||
| ADPT - NTRA | 52% Loosely correlated | +1.31% | ||
| GH - NTRA | 49% Loosely correlated | -0.82% | ||
| NEO - NTRA | 48% Loosely correlated | -0.29% | ||
| PSNL - NTRA | 48% Loosely correlated | -1.93% | ||
More | ||||